ASSOCIATO

e-mail: voso@med.uniroma2.it
Telefono: +39 06 7259 6280
SSD: MED/15
SC: 06/D3 
Macro-area:
Malattie del sangue, oncologia e reumatologia
Campi di interesse: 
- alterazioni genetiche ed epigenetiche nelle leucemie acute e sindromi mielodisplastiche, de novo e therapy-related
- diagnostica molecolare delle neoplasie ematologiche maligne e malattia minima residua
- protocolli clinici sperimentali per il trattamento della leucemie mieloidi acute e sindromi mielodisplastiche 


 

 Prof. Maria Teresa Voso

---

CURRICULUM VITAE
​

• 1990: Laurea in Medicina e Chirurgia, Universita’ Cattolica del Sacro Cuore, Roma
• 1992-1994: Stage di Ricerca presso il Laboratorio del Prof. Daniel G. Tenen, Harvard Medical School, Boston, USA.
• 1994: Specializzazione in Ematologia, Universita’ Cattolica del Sacro Cuore, Roma
• 1995: Medico borsista presso l’Istituto di Semeiotica Medica, Universita' Cattolica S. Cuore, Roma
• 1996-1999: Ricercatore presso l'Unita' Cooperativa Ematologia-Oncologia fra Universita` di Heidelberg e l’ Istituto tedesco per la Ricerca sul Cancro (DKFZ), Heidelberg, Germania
• 1999-2002: Dirigente Medico presso l’Istituto di Ematologia dell’ Universita’ Cattolica S. Cuore, Roma
• 2002-2014: Professore Aggregato, Istituto di Ematologia, Universita’ Cattolica Sacro Cuore, Roma, e dirigente medico presso il reparto di Ematologia, Policlinico Gemelli, Roma
• 2014- :Professore Associato di Malattie del Sangue, Universita’ di Roma Tor Vergata
• 2017: Idoneità a professore ordinario di ematologia
• 2019: Coordinatore del corso di Dottorato di Immunologia, Medicina molecolare e Biotecnologie applicate dell’università di Roma Tor Vergata
• 2020: Direttore UOSD Diagnostica Avanzata Oncoematologica del Policlinico di  Tor Vergata (PTV)

 
Metrics:       244 peer-reviewed full-text publications, H-index (WOS): 42

Pubblicazioni rilevanti

Rücker FG, ……Voso MT, …. Döhner K. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Leukemia 2021 Jul 28. Online ahead of print.

Mannelli F, …..Voso MT, … Vannucchi AM. AMELIORATE: early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance - MYNERVA-GIMEMA AML1919 trial. Future Oncol. 2021 Jul 13. Online ahead of print.

Fabiani E, … Voso MT. Mutational profile of ZBTB16-RARA-positive acute myeloid leukemia.Cancer Med 2021;10:3839-3847.

Trinh BQ, …. Voso MT, … Tenen DG. Myeloid lncRNA LOUP Mediates Opposing Regulatory Effects of RUNX1 and RUNX1-ETO in t(8;21) AML. Blood. 2021 May 10 Online ahead of print.

Larson RA, … Voso MT, .. Stone RM. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. Leukemia. 2021 Mar 2. Online ahead of print.

Bersanelli M, …Voso MT, .. Della Porta MG. Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. J Clin Oncol 2021;39:1223-1233.

Voso MT et al. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial.Blood Adv 2020;4:4945-4954.

Bernard E, …Voso MT, ….Papaemmanuil E. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med 2020;26:1549-1556.

Kuendgen A, … Voso MT, …Sanz G. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. Leukemia 2021;35:835-849.

Cicconi L, …. Voso MT, … Lo-Coco F. Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. Leukemia 2020;34:914-918.
 
Venditti A, … Voso MT, .. Amadori S. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Blood 2019;134:935-945.
Falconi G, …. Voso MT. Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes. Leukemia 2019;33:785-790.

Voso MT, et al. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. Ann Oncol 2017; 28:1547-1553
 
Fabiani E, …& Voso MT Clonal evolution in therapy-related neoplasms. Oncotarget 2017; 8: 12031-12040
 
Cicconi L, .., Voso MT, Mandelli F, Lo-Coco F. PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy. Leukemia 2016; 30: 1987-1992
 
Della Porta MG, … Voso MT, …Cazzola M. Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol 2016. pii: JCO673616
 
Fianchi L, …, & Voso MT. Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. Am J Hematol 2015; 90: 80-85
 
Voso MT, Lo-Coco F, Fianchi L. Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia. Curr Opin Oncol 2015; 27: 532-539
 
Voso MT, et al. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. J Clin Oncol 2013; 31: 2671-2677
 
Voso MT, et al Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases. Leukemia 2013; 27: 982-985
 
Voso MT, et al. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res 2009;15: 5002-7